Kite Pharma Ready To Jump Logistical Hurdles Of CAR-T
In an interview at the J.P. Morgan conference, Kite Pharma execs explain how the company is gearing up for the challenge of supplying CAR-T therapy for multicenter trials and commercializing a product in 2017.
You may also be interested in...
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.